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Sodium valproate (VPA) is considered the first choice drug in juvenile myoclonic epilepsy (JME). We have analysed the long-
term evolution of 22 patients treated from the outset with VPA.
The following inclusion criteria were applied: (1) unequivocal diagnosis of JME; (2) treatment should be initiated with VPA
monotherapy; and (3) follow-up for more than 5 years.
Twenty-two patients (15 females, seven males) were studied and their EEG recordings were analysed. Their mean age was
28 years (range: 20–40 years) and their mean follow-up was 7.7 years (range: 5–17 years). Four of them suffered persistent
seizures despite optimal VPA dosage and needed the addition of a second drug (lamotrigine in three cases, clobazam in one
case). All of our patients who continued their treatment are seizure-free. VPA effectively controlled all seizures in 80% of
patients. The discontinuation of drug therapy lead to a very high rate of relapses.
With accurate diagnosis and appropiate therapy, seizures in JME can be effectively controlled. VPA is a very effective
antiepileptic drug in controlling the seizures of JME, but many patients relapse after VPA discontinuation. Thus, JME may
require lifelong therapy.
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INTRODUCTION
Juvenile myoclonic epilepsy (JME) is a common form
of idiopathic generalized epilepsy that typically oc-
curs in adolescence. Its clinical features and electroen-
cephalographic findings are well known1–7. Sodium
valproate (VPA) is considered the first choice drug
in JME8. However, there are few published long-term
follow-up reports of patients treated from the onset
with VPA9.
PATIENTS AND METHODS
One hundred and twenty patients with JME are
controlled in our Neurological Department. For the
present study we applied the following inclusion cri-
teria: (1) unequivocal diagnosis of JME (evidence
of myoclonic seizures beginning from the age of 8
upto 20 years of age; no evidence of neurological or
intellectual deficit; abnormal EEG with generalized
spike-wave and/or multiple spike-wave discharges);
(2) treatment should be initiated with VPA monother-
apy; and (3) follow-up for more than 5 years.
RESULTS
Twenty-two patients (15 female, seven male) with a
mean age of 28 years (range: 20–40 years) and a
mean follow-up 7.7 years (range: 5–17 years) were
studied. All the patients had myoclonic seizures,
15 (68%) had myoclonic seizures and generalized
tonic–clonic seizures (GTCS), four (18%) had my-
oclonic seizures, GTCS and absence seizures, and
three patients (13.6%) had only myoclonic seizures.
An average of two (range: 0–8) GTCS was reported.
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An average of 0.7 GTCS (range: 0–4) was reported af-
ter the onset of VPA treatment.
Myoclonic seizures began on average at 16.5 years
(range: 12–22 years); GTCS began on average at
17.8 years (range: 14–30 years). The average age at
which JME was definitively diagnosed was 18.9 years
(range: 13–27 years), after a mean of 2.4 years (range:
0–12 years) from the onset of the myoclonic seizures.
Treatment with VPA was initiated at an average age
of 17.4 years (range: 13–24 years). Four patients con-
tinued suffering GTCS and a second antiepileptic drug
was added to VPA: three of them were controlled
on a combination of VPA and lamotrigine; another
one was eventually controlled on a combination of
VPA and clobazam. Two patients chose voluntarily to
discontinue the treatment, and they suffer occasional
myoclonic jerks. Another discontinued the treatment
on medical orders and she remains seizure-free after
5 years of follow-up (progressive dose reduction was
not followed by relapses). Only one (4.4%) patient was
receiving anxiolytic treatment with benzodiazepines
Twenty patients (90.9%) became seizure-free: six
of them (27.3%) have remained seizure-free for more
than 5 years. Of these patients, five were receiving
VPA monotherapy. The other one was not receiving
any treatment at all. Only two patients (9.1%) occa-
sionally relapse. All patients who did not discontinue
medication are seizure-free. Of them, 16 relapsed, af-
ter attempts to reduce the dose of VPA: three patients
developed GTCS and 13 had only myoclonic seizures
(Fig. 1).
The average daily dose of VPA was 850 mg per day
(range: 500–1500 mg per day) and the average blood
levels were 513 µmol l−1 (range: 35–908 µmol l−1).
The average dose of lamotrigine was 165 mg (range:
100–200 mg per day).
We reviewed 148 EEG recordings. Each patient
had a mean of 6.7 EEG recordings. At the time of
the first record 40.9% of the patients were receiv-
ing VPA. Only 56% of their standard EEG recordings
had pathological findings, whereas 89% of their sleep
EEGs showed paroxysmal abnormalities. Among the
patients who were not receiving antiepileptic drugs
at the time of the first recordings, 69% of the stan-
dard EEGs had pathological findings, whereas 100%
of their sleep EEGs showed paroxysmal abnormalities.
Normal standard EEGs were reported in every patient
during the follow-up, although they did occasionally
show paroxysmal abnormalities, but 89% of the sleep
EEGs at the follow-up continued show pathological
findings.
Nine patients (40.9%) displayed a photoparoxysmal
response. This occurred in six (67%) females and three
(33%) males. The patients that have remained seizure-
free for more than 5 years have a lower rate of pho-
toparoxysmal response (16%).
Focal abnormalities were noted in at least one EEG
in six (27.3%) of the 22 patients (five females (83.3%)
and one male (16.7%)).
DISCUSSION
Despite the distinctive features of JME and the sig-
nificance of diagnosis for management and prognosis,
JME is widely underdiagnosed5. In our patients the
correct diagnosis was made after a mean of 2.4 years
(range: 0–12 years) from the onset of the disease. This
is in reality a lower interval than the 14.5 years referred
to by Gru¨newald et al.10 or the 10.6 years detected by
Salas-Puig et al.6 The latter studied a population sim-
ilar to ours 10 years earlier. Thus, the diagnosis yield
can be improved with heightened medical awareness.
JME is characterized by myoclonic jerks, occur-
ring mainly on awakening and often associated with
GTCS and typical absence seizures in an age-related
sequence. The clinical characteristics of our patients
compare well with those of previous reports. An im-
portant feature in our patients was that only an average
of 0.7 GTCS (range: 0–4) were reported after the onset
of VPA treatment.
According to the original description by Janz and
Christian1, patients often have an unstable personal-
ity, which may lead to social maladjustment. However
no particular psychiatric condition can be considered
as significantly associated. Salas-Puig et al.6 reported
that 13% of their patients were being treated with ben-
zodiazepines, antidepressants or even neuroleptics. In
our study only one patient (4.5%) is receiving anxy-
olitic treatment. This figure suggests that an early and
appropiate therapy probably would prevent the appear-
ance of psychopathological disorders.
Interictal and ictal EEG findings are very character-
istic11. The EEG in untreated patients usually shows
generalized spike or multiple spike/wave discharges.
Focal abnormalities are common12. These consist on
either focal onset of the generalized discharge or focal
slow waves that may be unilateral or may shift sides.
Spontaneous jerks are always associated with general-
ized multiple spike-wave discharges.
Photoparoxysmal responses (PPR) have been found
in 33% of the patients for Asconape´ and Penry2, 32%
for Salas-Puig et al.6, 27% for Panayiotopoulos et al.7
and 33% for Gru¨newald et al.10. We found PPR in 30%
of our patients at the time of the first EEG recording,
but in only 5% at the follow-up.
Photosensitivity is more common in females than
in males (67% of our photosensitive patients were fe-
males). Among the patients of our study with a better
evolution (those who have been seizure-free for more
than 5 years) only 16% had EEG evidence of photo-
sensitivity.
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Fig. 1: Antiepileptic drugs during follow-up and clinical response. VPA, sodium valproate; CLB, clobazam; LTG, lamotrigine.
Numbers of patients are given in parentheses.
Apparently focal paroxysmal abnormalities were
noted in 27.3% of our patients. These focal EEG ab-
normalities were found in 15% of the patients by
Salas-Puig et al.6 and in 30% by Asconape´ and
Penry2.
Among the patients of our study who were not being
treated at the time of the first EEG recording, a typical
pattern of paroxysmal abnormalities was found in 69%
of the standard EEG recordings, but in 100% of the
sleep recordings during a nap period. At the follow-up
100% of the patients had normal standard EEG records
(though eventually paroxysmal abnormalities could be
found). However, 89% of the sleep EEGs at the follow-
up continued to show pathological findings. A sleep
EEG recording should be requested when the routine
EEG is normal and further confirmation of the diagno-
sis is required.
Patients should be warned of the common seizure
precipitants. The most effective antiepileptic drug
for this condition is VPA, and most authors recom-
mend lifelong therapy8. If seizures persist despite this
treatment patients may benefit from the addition of
lamotrigine.
All of our patients were treated from the outset
with VPA monotherapy. Eighteen point two percent
of them, with persistent GTCS despite optimal VPA
dosage, were treated by adding small doses of a sec-
ond drug: lamotrigine in three cases (they were com-
pletely controlled and they continued this treatment
during follow-up) and clobazam in one case (this
patient was completely controlled and clobazam was
discontinued).
Three patients have discontinued all treatment: two
of them withdrew VPA voluntarily and they are the
only patients of our study who continue suffering
myoclonic seizures; in another one VPA was able to
be discontinued without relapses. This patient seems
to have a very benign form of JME. When we analysed
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her case, however, we were not able to find any
characteristic that would have made us suspect a
good outcome. Her awake EEG is normal but her
sleep EEG recording continues to show paroxysmal
abnormalities.
All of our patients who continue their treatment are
seizure-free. The reported effective control of seizures
ranges from 54% (Asconape´ and Penry2) to 95%
(Christe9). Antiepileptic drugs and periods of follow-
up are heterogeneous. The drug of choice, however, is
currently VPA on monotherapy which effectively con-
trolled all seizures in 73% of our patients in spite of
low doses and low blood levels.
The discontinuation of drug therapy leads to a
very high rate of relapse. In our study 73% of the
patients have suffered relapses. These occurred weeks
or months after the discontinuation of treatment in
all of our patients except for one. Relapses occurred
as GTCS in three of the relapsing patients (18.7%);
13 of them (81.2%) had only myoclonic relapses.
These rates compare well with those reported by Janz4
(91%) and Penry8 (50%) and suggest that treatment
should not be discontinued even after patients have
been seizure-free for a long time.
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